Pablo G. Legorreta - 06 Aug 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role: CEO, Chairman of the Board, Director
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta
Issuer symbol: RPRX
Transactions as of: 06 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 08 Aug 2025, 17:00:00 UTC
Previous filing: 05 Jun 2025
Next filing: 07 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Legorreta Pablo G.	CEO, Chairman of the Board, Director	C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK	/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta	08 Aug 2025	0001507678

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPRX	Class A Ordinary Shares	Award	$0	+21,901	+2.5%	$0.000000	904,396	06 Aug 2025	Direct	F1
holding	RPRX	Class A Ordinary Shares						460,139	06 Aug 2025	By Legorreta Investments LLC
holding	RPRX	Class A Ordinary Shares						123,310	06 Aug 2025	By IRRA
holding	RPRX	Class A Ordinary Shares						118,500	06 Aug 2025	By SEP/IRA
holding	RPRX	Class A Ordinary Shares						1,040,410	06 Aug 2025	By Legorreta Children 2002 Trust
holding	RPRX	Class A Ordinary Shares						901,590	06 Aug 2025	By GST-Exempt Legorreta 2012 Family Trust
holding	RPRX	Class A Ordinary Shares						41,306	06 Aug 2025	By GST-Exempt Legorreta 2020 Family Trust
holding	RPRX	Class A Ordinary Shares						6,930	06 Aug 2025	By Spouse
holding	RPRX	Class A Ordinary Shares						292,190	06 Aug 2025	By Tata MC 35 Ltd.
holding	RPRX	Class A Ordinary Shares						10,000	06 Aug 2025	By Son
holding	RPRX	Class A Ordinary Shares						10,000	06 Aug 2025	By Daughter
holding	RPRX	Class A Ordinary Shares						600,000	06 Aug 2025	By Legorreta 2023 SR Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RPRX	LP interests in RPI US Partners 2019, LP	Gift	$0	-60,000	-8%	$0.000000	692,701	08 Aug 2025	Class A Ordinary Shares	600,000		Direct	F2, F3
holding	RPRX	LP interests in RPI US Partners 2019, LP						3,707,488	06 Aug 2025	Class A Ordinary Shares	37,074,880	$0.000000	By Legorreta Investments LLC	F3
holding	RPRX	LP interests in RPI US Partners 2019, LP						1,832,363	06 Aug 2025	Class A Ordinary Shares	18,323,630	$0.000000	By Legorreta Investments II LLC	F3
holding	RPRX	LP interests in RPI US Partners 2019, LP						147,014	06 Aug 2025	Class A Ordinary Shares	1,470,140	$0.000000	By Spouse	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
F2	No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.
F3	Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.